A randomized study of docetaxel plus cisplatin versus paclitaxel plus cisplatin in previously untreated advanced non-small cell lung cancer

A randomized study of docetaxel plus cisplatin versus paclitaxel plus cisplatin in previously untreated advanced non-small cell lung cancer

Background and objective Docetaxel is an active agent in the second-line treatment for non-small cell lung cancer (NSCLC), many clinical trials have demonstrated that it has similar efficacy to common first-line regimens for NSCLC. A randomized study was conducted to compare docetaxel plus cisplatin...

Full description

Bibliographic Details
Main Authors: Haiyong WANG, Yanfei GU, Xi LI, Xinjie YANG, Fanbin HU, Qunhui WANG, Shucai ZHANG, Jinghui ZHANG
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2008-02-01
Series:Chinese Journal of Lung Cancer
Subjects:
Docetaxel
Paclitaxel
Cisplatin
Antineoplastic combined chemotherapy protocols
Non-small cell lung cancer
Online Access:http://www.lungca.org/index.php?journal=01&page=article&op=view&path%5B%5D=10.3779%2Fj.issn.1009-3419.2008.01.024&path%5B%5D=30

Internet

http://www.lungca.org/index.php?journal=01&page=article&op=view&path%5B%5D=10.3779%2Fj.issn.1009-3419.2008.01.024&path%5B%5D=30

Similar Items